Zydus Cadila has received the tentative approval from the United States Food & Drug Administration (USFDA) to market Tadalafil Tablets USP in the strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg.

The drug is indicated for the treatment of erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 170 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 5.55, or 1.25%, to trade at Rs 449.05. The total volume of shares traded was 21,825 at the BSE (10.06 a.m., Friday).